ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation

Song-Hui Xu¹², Song Zhu¹², Yanjie Wang¹, Jin-Zhou Huang¹, Min Chen¹², Qing-Xia Wu¹, Yu-Tian He¹, De Chen¹² and Guang-Rong Yan¹²

Abstract
The human ortholog of the Drosophila ecdysoneless gene (ECD) is required for embryonic development and cell-cycle progression; however, its role in cancer progression and metastasis remains unclear. Here, we found that ECD is frequently overexpressed in gastric cancer (GC), especially in metastatic GC, and is correlated with poor clinical outcomes in GC patients. Silencing ECD inhibited GC migration and invasion in vitro and metastasis in vivo, while ECD overexpression promoted GC migration and invasion. ECD promoted GC invasion and metastasis by protecting hnRNP F from ubiquitination and degradation. We identified ZFP91 as the E3 ubiquitin ligase that is responsible for hnRNP F ubiquitination at Lys 185 and proteasomal degradation. ECD competitively bound to hnRNP F via the N-terminal STG1 domain (13-383aa), preventing hnRNP F from interacting with ZFP91, thus preventing ZFP91-mediated hnRNP F ubiquitination and proteasomal degradation. Collectively, our findings indicate that ECD promotes cancer invasion and metastasis by preventing E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation, suggesting that ECD may be a marker for poor prognosis and a potential therapeutic target for GC patients.

Introduction
Gastric cancer (GC) is a prevalent malignancy in East Asian countries, including China, and is the second leading cause of cancer-related mortality worldwide, with an overall 5-year survival rate of less than 25%¹². Most GCs are diagnosed clinically at an advanced disease stage and thus present with distant metastases, which are the most important cause of cancer-associated death in GC patients. Although surgical resection is considered the gold standard for treating GC patients, GC patient prognosis remains poor due to the high incidence of tumor recurrence and distant metastasis. Conventional chemotherapy has limited effects on GC, especially metastatic GC. Targeted small molecule or antibody therapies designed to inhibit a specific oncogene are promising therapeutic strategies. Anti-HER2-targeted antibody therapies improve the overall survival of HER2-positive GC patients when combined with chemotherapy; however, HER2-positive patients comprise only 7–17% of GC patients. Therefore, new therapeutic targets are urgently needed.

The ecdysoneless (ECD) gene was originally named by authors studying Drosophila melanogaster ECD mutants who exhibited defective development due to reduced production of the steroid hormone, ecdysone, required for insect molting³. Subsequent studies showed that the ECD protein is required for cell-autonomous processes in Drosophila development and oogenesis⁴. The human ECD homolog was initially identified in a complementation assay conducted to rescue yeast mutants lacking the
glycolysis regulation 2 (Gcr2) gene. ECD gene deletion in mouse embryonic fibroblasts led to cell-cycle arrest at the G1/S checkpoint, suggesting ECD is a novel cell-cycle regulator. ECD is overexpressed in pancreatic and HER2/ErbB2-overexpressing breast cancers. Our previous studies showed that ACK1 promotes GC metastasis through the AKT-POU2F1-ECD pathway and that ECD is a potential key downstream effector of ACK1. However, the roles and molecular mechanisms of ECD in cancer progression and metastasis remain unknown.

hnRNP F belongs to the hnRNP family, a large family of RNA-binding proteins that regulate multiple aspects of nucleic acid metabolism, including alternative splicing, transcription, translation, and mRNA stabilization. hnRNP expression is altered in many cancers, and these proteins are crucial in cancer cell proliferation, invasion, and metastasis. hnRNP F/H regulate alternative splicing of the apoptotic regulator, Bcl-x, and the tumor-associated NADH oxidase, ENOX2. hnRNP F is a potential marker for colorectal cancer progression; however, the regulatory mechanism of hnRNP F expression upregulation in cancers remains unknown.

Ubiquitination is a well-studied post-translational modification involved in proteasomal degradation, protein–protein interaction, protein trafficking, and protein activity. Protein ubiquitination is mediated by three enzyme families (E1, E2, and E3). Ubiquitination system activity depends on E3 ubiquitin ligase specificity. To date, a direct connection between hnRNP F and the ubiquitination pathways remains unobserved, as an hnRNP F-specific E3 ligase that can bind to hnRNP F and induce ubiquitination and proteasomal degradation of hnRNP F has not been identified.

In this study, we found that ECD was overexpressed in GC, especially in metastatic GC, and ECD promotes GC invasion and metastasis by stabilizing hnRNP F. We further found that ZFP91 is the E3 ligase responsible for hnRNP F ubiquitination at Lys 185 and degradation. ECD blocks the interaction between ZFP91 and hnRNP F and the subsequent ubiquitination- and degradation-inducing effects of ZFP91 on hnRNP F by competitively binding to

---

**Fig. 1** ECD expression is increased in GC and is correlated with a poor prognosis in GC patients. 

- **A** The indicated protein levels in six pairs of primary GC samples (T) and matched adjacent non-tumoral gastric tissue samples (N) were detected.
- **B** ECD mRNA expression levels were increased in GC compared with those in gastric mucosa, as determined by analyses of three gastric databases from Oncomine.
- **C** Representative IHC images of ECD expression in the GC tissue specimens and the corresponding N tissue specimens.
- **D** The differences in ECD expression scores between the GC tissue specimens and the corresponding N tissue specimens are presented as a box plot.
- **E** Kaplan–Meier survival analysis of patients with GC by their ECD levels.

---

Official journal of the Cell Death Differentiation Association
hnRNP F. Our findings indicate that ECD facilitates cancer migration and invasion by stabilizing hnRNP F, and ECD may be used as a novel prognostic GC biomarker, as well as an anti-cancer therapeutic target.

Results
ECD overexpression is correlated with aggressive GC phenotypes
To investigate the role of ECD in gastric progression, we analyzed ECD protein levels in six pairs of primary GC tissue samples and matched adjacent non-tumoral gastric tissue (N) samples. We found elevated ECD protein levels in all GC tissue samples compared to those in the N samples (Fig. 1a). We also investigated ECD mRNA expression in gastric mucosal tissues and GC tissues using three microarray gene expression datasets deposited in the Oncomine database. ECD mRNA levels were higher in gastric intestinal-type adenocarcinoma and gastric adenocarcinoma tissues than in gastric mucosal tissues (Fig. 1b), indicating that ECD expression is upregulated in GC.

To investigate the correlation between ECD levels and prognosis, we performed an extensive tissue microarray analysis of 186 GC tissue samples and 154 adjacent non-tumoral gastric tissue (N) samples (including 149 GC tissue pairs and matched non-tumoral gastric tissues) using an immunohistochemical (IHC) assay (Fig. 1c). We detected higher ECD levels in GC tissues than in N tissues (Fig. 1d), as well as higher ECD levels in metastatic GC tissues than in non-metastatic GC tissues (Fig. 1e). ECD overexpression was positively associated with pT status, pN status, lymph node metastasis, more advanced histological grades and clinical stage in GC (Table 1). GC patients with high ECD levels were at higher risk for cancer-related death than those with low ECD levels (Fig. 1f, g). The mean overall survival time for GC patients with high ECD levels was 19.5 months, while for GC patients with low ECD levels, it was 45.5 months ($p = 0.0005$, log-rank test). Therefore, ECD overexpression was correlated with poor prognosis in GC patients.

ECD promotes GC invasion and metastasis
To investigate the role of ECD in GC invasion and metastasis, we either silenced or overexpressed ECD in two GC cell line models. ECD silencing suppressed GC cell migration and invasion in SGC-7901 and MGC-803 cells (Fig. 2a), while ECD overexpression promoted GC cell migration and invasion in those cells (Fig. 2b).

Smaller metastatic nodules developed in mouse lungs after injection with luciferase-tagged SGC-7901 cells with stable silencing of ECD expression than those in mouse lungs after injection with SGC-7901 cells (Fig. 2c). Smaller metastatic lung nodules were also confirmed by histological analysis (Fig. 2d). Collectively, these results indicate that ECD promotes GC cell migration and invasion in vitro and metastasis in vivo.

ECD interacts with hnRNP F via the SGT1 domain
To investigate the mechanism by which ECD promotes cancer invasion and metastasis, we identified the proteins that interact with ECD by performing Co-IP and mass spectrometry analyses (Fig. 3a). We identified that hnRNP F might interact with ECD. We further confirmed that ECD interacts with hnRNP F (Fig. 3b).

ECD consists of a conserved SGT1 domain and trans-activation region. To determine which domains interact with hnRNP F, we generated truncated ECD constructs with an N-terminal Flag tag (Fig. 3c). When these constructs were co-expressed with HA-hnRNP F in cells, only the constructs containing the ECD N-terminal STG1 domain (13-383aa), but no other ECD regions, could

Table 1 Correlations between the expression of ECD and clinicopathological features in 186 GC cases

| Clinicopathological Features | All cases | Low $^b$ | High $^c$ | $X^2$ test | P value |
|-----------------------------|-----------|---------|---------|----------|--------|
| Sex                         |           |         |         |          |        |
| Female                      | 66        | 27      | 39      |          | 0.118  |
| Male                        | 120       | 46      | 74      |          | 0.745  |
| Age (years) $^d$            |           |         |         |          |        |
| ≤60                         | 93        | 39      | 54      | 0.480    | 0.488  |
| >60                         | 92        | 34      | 58      |          |        |
| Histological Grade          |           |         |         |          |        |
| G1–G2                       | 42        | 23      | 19      |          |        |
| G3                          | 144       | 50      | 94      | 5.477    | 0.019  |
| Metastasis                  |           |         |         |          |        |
| No                          | 112       | 52      | 60      |          | 6.089  |
| Yes                         | 74        | 21      | 53      |          | 0.014  |
| pT status                   |           |         |         |          |        |
| I–II                        | 30        | 29      | 1       |          | 50.642 |
| III–IV                      | 156       | 43      | 113     |          | 0.000  |
| pN status $^d$              |           |         |         |          |        |
| I–II                        | 114       | 56      | 58      | 11.611   | 0.001  |
| III                         | 71        | 17      | 54      |          |        |
| Clinical stage $^d$         |           |         |         |          |        |
| I–II                        | 65        | 43      | 22      |          | 30.814 |
| III                         | 119       | 29      | 90      |          | 0.000  |

$^aX^2$ test.

$^b$ECD expression score is 0–5.

$^c$ECD expression score is 6–7.

$^d$All case number is less than 186 because the clinicopathological information of some cases is absent or clear.
interact with hnRNP F, indicating that the N-terminal STG1 domain is essential for hnRNP F binding (Fig. 3d).

ECD increases hnRNP F protein levels by inhibiting hnRNP F polyubiquitination and degradation

How does ECD affect hnRNP F given that ECD can bind to hnRNP F? To address this, we investigated the effects of ECD on hnRNP F protein and mRNA levels. ECD silencing decreased hnRNP F protein levels, but not hnRNP F mRNA levels (Fig. 4a, b), while ECD overexpression increased hnRNP F protein levels, but not hnRNP F mRNA levels, in a dose-dependent manner (Fig. 4c, d), indicating that ECD upregulated hnRNP F protein levels at the post-transcriptional level.

Because ECD may upregulate hnRNP F protein levels, and the ubiquitination/proteasome pathway is the quickest known mechanism through which proteins are irreversibly degraded\(^20,23,24\), we surmised that ECD upregulated hnRNP F by preventing its ubiquitination. To test this hypothesis, we determined the effect of ECD overexpression on the half-life of hnRNP F. As shown in Fig. 4e, ECD overexpression resulted in a longer hnRNP F half-life. We also performed an in vivo ubiquitination assay, which showed that silencing ECD in the presence of MG132 (a specific proteasome inhibitor) increased hnRNP F polyubiquitination levels (Fig. 4f). Collectively, our results strongly indicate that ECD inhibits hnRNP F protein polyubiquitination and proteasomal degradation, thus increasing hnRNP F protein levels.

Furthermore, we investigated the correlation between ECD and hnRNP F protein levels in GC tissues. We found that hnRNP F protein levels were upregulated in GC tissues compared with those in matched N tissues, consistent with the results of the ECD expression experiments (Fig. 1a). Extensive tissue microarray analysis showed that hnRNP F protein levels were higher in GC tissues than in N tissues (Fig. 4g); however, hnRNP F mRNA levels were unchanged between GC tissues and N gastric tissues (Supplementary Fig. S1). ECD protein levels were also positively correlated with hnRNP F protein levels in GC tissue samples \((R = 0.314, p < 0.0001)\) (Fig. 4h). These findings indicate that ECD increases hnRNP F protein levels by stabilizing hnRNP F.
ECD stimulates GC migration and invasion by stabilizing hnRNP F

Next, we investigated the role of hnRNP F in ECD functions. We found that silencing of hnRNP F inhibited GC cell migration and invasion, similar to the effects induced by ECD knockdown (lane 3 in Supplementary Fig. S2B). And silencing hnRNP F attenuated the enhanced migration and invasion induced by ECD over-expression (Supplementary Fig. S2), indicating that ECD promotes GC migration and invasion by regulating hnRNP F stability.

ZFP91 is an E3 ubiquitin ligase responsible for ubiquitinating hnRNP F

As ECD is not an E3 ligase, and the E3 ligase responsible for hnRNP F ubiquitination remains unknown, we sought to identify the E3 ligase that regulates hnRNP F protein ubiquitination and degradation. E3 ligases must bind to their substrates to facilitate their ubiquitination. Thus, we identified the proteins that interacted with hnRNP F by performing Co-IP and a mass spectrometry assay to identify the E3 ligase responsible for ubiquitinating hnRNP F. We found that ZFP91 is the potential E3 ligase because it can bind to hnRNP F (Fig. 5a). We further confirmed that ZFP91 interacts with hnRNP F (Fig. 5b, c), thus suggesting that ZFP91 may be the E3 ligase responsible for polyubiquitinating hnRNP F.

To determine whether ZFP91 is the E3 ligase responsible for hnRNP F ubiquitination, we investigated the effects of ZFP91 on hnRNP F mRNA and protein levels, half-life and ubiquitination. We found that silencing ZFP91 increased hnRNP F protein levels, but not hnRNP F mRNA levels, while ectopically expressing ZFP91 decreased hnRNP F protein levels, but not hnRNP F mRNA levels (Fig. 5d, Supplementary Fig. S3). Moreover, ZFP91 overexpression resulted in a shorter hnRNP F protein half-life (Fig. 5e), and our in vivo ubiquitination assay results showed that ZFP91 overexpression increased hnRNP F polyubiquitination levels in the presence of the specific proteasome inhibitor, MG132 (Fig. 5f). This indicates that ZFP91 is the E3 ligase responsible for ubiquitinating and degrading hnRNP F.
ZFP91 induces hnRNP F ubiquitination at Lys 185

To identify the specific ubiquitination modification lysine sites in the hnRNP F protein, we searched the PhosphoSitePlus post-translational modification resource. Four potential ubiquitination sites at lysine residues were found in the hnRNP F protein (Supplementary Fig. S4A). We subsequently generated hnRNP F mutants in which these lysine residues were replaced with arginine. We found that ZFP91 overexpression did not change the protein levels in the hnRNP F mutant with K185R, but it decreased the protein levels in the hnRNP F mutants with K87R, K167R, or K171R (Fig. 5g). ZFP91 overexpression also increased the hnRNP F mutant polyubiquitination levels with K87R, K167R, or K171R, but not in the mutant with K185R (Fig. 5h). These data indicate that hnRNP F ubiquitination at Lys 185 was regulated by ZFP91 E3 ligase.

We further investigated the effects of hnRNP F ubiquitination at Lys 185 on ZFP91-mediated cancer cell migration and invasion. We found that ZFP91 overexpression inhibited GC cell migration and invasion, thus exerting effects that contrast with those of hnRNP F (Supplementary Fig. S4B). ZFP91 co-expression also attenuated the enhanced migration and invasion induced by overexpressing the hnRNP F mutants with K87R, K167R, or K171R, as ZFP91 polyubiquitinated these hnRNP F mutants and facilitated their subsequent degradation by the proteasome; however, ZFP91 co-expression did not block the enhanced migration and invasion induced by overexpressing the hnRNP F mutant with K185R because this protein was not polyubiquitinated and was degraded by ZFP91 (Supplementary Fig. S4B). Collectively, our results indicate that ZFP91 polyubiquitinated hnRNP F at Lys 185.

ECD blocks ZFP91 from binding to hnRNP F

We further investigated, and subsequently found, an interaction between ECD and ZFP91 (Fig. 6a, b). The constructs containing the ECD N-terminal STG1 domain (13-383aa), but not other ECD regions, retained interactions with ZFP91 (Fig. 6c), suggesting that the same ECD domain that bound to hnRNP F interacted with ZFP91.
Because ECD binds to ZFP91 and hnRNP F, and ZFP91 binds to hnRNP F, we surmised that ECD inhibits the interaction between ZFP91 and hnRNP F. We cotransfected ZFP91, hnRNP F, and ECD plasmids into HeLa cells and assessed the protein interactions. We found that ECD overexpression dose-dependently blocked the ZFP91 and hnRNP F interactions (Fig. 6d, e). Furthermore, we found that the constructs containing the ECD N-terminal STG1 domain (13-383aa), but not other ECD regions, blocked the ZFP91 and hnRNP F interactions (Fig. 6f). This indicates that ECD blocked ZFP91 from binding to hnRNP F through the N-terminal STG1 domain.

**ECD blocks ZFP91-mediated hnRNP F ubiquitination and degradation**

Because ZFP91 is an E3 ubiquitin ligase that acts on hnRNP F, and ECD blocks the interaction between ZFP91 with hnRNP F and inhibits hnRNP F degradation, we surmised that ECD blocks ZFP91-mediated hnRNP F ubiquitination and degradation. We co-transfected ZFP91, hnRNP F, and ECD plasmids into HeLa cells and investigated hnRNP F protein and ubiquitination levels. ECD reversed the decreased hnRNP F protein levels induced by ZFP91 overexpression (Fig. 7a). In addition, ECD dose-dependently blocked the enhanced hnRNP F ubiquitination levels induced by ZFP91 overexpression (Fig. 7b, c).
We further investigated whether the ECD N-terminal STG1 domain can block ZFP91-mediated hnRNP F ubiquitination, as this domain blocked the interaction between ZFP91 and hnRNP F. The mutants containing the ECD N-terminal STG1 domain exerted effects similar to wild-type ECD and blocked the increased hnRNP F polyubiquitination levels induced by ZFP91, while the mutants containing other ECD regions did not (Fig. 7d). This indicates that ECD blocks ZFP91-mediated hnRNP F ubiquitination and degradation through the N-terminal STG1 domain.

**Discussion**

We found that ECD induces cancer invasion and metastasis, and we elucidated the novel mechanism underlying ECD’s effect on cancer progression. Specifically, we found that ECD stabilizes hnRNP F, by blocking the interaction between ZFP91 and hnRNP F and the subsequent ubiquitination and degradation of hnRNP F by ZFP91. ZFP91 is an E3 ubiquitin ligase that ubiquitinates hnRNP F at Lys 185.

Initial studies demonstrated that the Drosophila ECD is required for embryonic development. Here, we demonstrated that human ECD homolog levels were significantly increased in GC tissues, especially in metastatic GC tissues, compared with those in adjacent non-tumoral gastric tissues. ECD mRNA levels were also increased in GC tissues compared with those in the gastric mucosa tissues in three HCC datasets deposited in the Oncomine database. These results indicated that ECD upregulation in GC was induced at the transcriptional level, consistent with our previous study in which we observed that ACK1 stimulated the transcription factor POU2F1 to induce ECD transcription. ECD overexpression was significantly associated with aggressive GC phenotypes, as GC patients with high ECD levels...
exhibited higher death rates and shorter survival times than GC patients with low ECD levels. Our findings suggest that ECD may be a novel independent prognostic factor in GC patients. Silencing ECD significantly suppressed GC metastasis and invasion in vitro and in vivo, indicating that ECD may be a novel therapeutic target for GC.

Previous studies reported that ECD promotes cell proliferation by regulating RB/E2F pathway-dependent cell-cycle progression and GLUT4-dependent glycolysis in breast and pancreatic cancer, respectively. Here, we elucidated a novel mechanism underlying the effects of ECD on GC invasion and metastasis. We showed that ECD promoted GC metastasis and invasion by stabilizing hnRNP F. We found that ECD bound to hnRNP F to prevent E3 ligase ZFP91 from interacting with hnRNP F, thus blocking ZFP91-mediated hnRNP F polyubiquitination at Lys 185 and increasing hnRNP F protein levels to promote cancer metastasis and invasion. Previous studies showed that hnRNP F mRNA levels were increased by OKI-6 in myelinating glia. In this study, we discovered a novel mechanism through which hnRNP F is upregulated by ECD blocking the ubiquitin/proteasome pathway. The double bands for hnRNP F were detected; the possible causes include the different isoform of hnRNP F and the cleaved hnRNP F.

ZFP91 is a novel E3 ligase that activates the NF-κB-inducing kinase (NIK) via Lys63-linked ubiquitination in the noncanonical NF-κB signaling pathway. Here, we noted that in addition to activating substrates via ubiquitination, ZFP91 also interacted with and promoted the ubiquitination of hnRNP F at Lys 185, as well as its subsequent degradation by the proteasome. Here, we report for the first time that ZFP91 is an E3 ligase that ubiquitinates and degrades hnRNP F.

In conclusion, we found that ECD is overexpressed in GC, especially in metastatic GC, and that ECD overexpression is correlated with a malignant phenotype and poor prognosis for GC patients. We elucidated the novel molecular mechanism underlying the effects of ECD in cancer progression, as we determined that ECD promotes invasion and metastasis by stabilizing hnRNP F. We further demonstrated that ECD competitively bound to hnRNP F through the N-terminal STG1 domain to

Fig. 7 ECD blocks ZFP91 E3 ligase-mediated hnRNP F protein ubiquitination and degradation. a The indicated plasmids were transfected into HeLa cells, and the indicated protein expression levels were determined. b HeLa cells were co-transfected with the indicated plasmids for 36 h, then treated with 10 μM MG132 for 4 h. The hnRNP F polyubiquitination pattern was analyzed as described in Fig. 4f. c His-ECD vectors and the indicated plasmids were transfected into HeLa cells at the indicated doses. The hnRNP F polyubiquitination pattern was analyzed as described in Fig. 4f. d The indicated Flag-ECD mutants and plasmids were transfected into HeLa cells. The hnRNP F polyubiquitination pattern was analyzed as described in Fig. 4f. e A proposed model illustrating that ECD promotes cancer metastasis by blocking the ZFP91 E3 ligase from binding to hnRNP F, and the subsequent ubiquitination and degradation of hnRNP F by ZFP91 E3 ligase.
prevent ZFP91-mediated hnRNP F ubiquitination and degradation. We discovered the E3 ligase, ZFP91, which is responsible for hnRNP F ubiquitination and degradation at Lys 185. Our findings indicate that ECD may be a new prognostic factor and potential anti-cancer target for GC.

Materials and Methods

Cell culture and tissue samples
HeLa cells were obtained from and authenticated by ATCC. The GC cell lines, SGC-7901 and MGC-803, were obtained from and authenticated by isoenzyme assay by the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China)\textsuperscript{28}. The cells were cultured as previously described\textsuperscript{1,9}. All cell lines were treated with Plasmocin and tested with Mycoplasma PCR Detection Kit (Sigma-Aldrich, USA). Primary GC tissue samples and matched adjacent non-tumoral gastric tissue samples were collected at The Third Affiliated Hospital of Guangzhou Medicine University. Samples with a clear pathological diagnosis were selected and obtained from GC patients who had not received preoperative anti-cancer treatment. Informed consent was obtained from each patient who participated in the study, and tissue sample collection was approved by the Internal Review and Ethics Boards of The Third Affiliated Hospital of Guangzhou Medicine University. Tissue microarray chips containing GC tissue samples and matched adjacent non-tumoral gastric tissue samples along with their corresponding clinicopathological data were obtained from Shanghai OUTDO Biotech Co., Ltd. (Shanghai, China).

Immunohistochemistry (IHC) staining assay
IHC staining assays were performed on tissue microarray chips with anti-ECD and anti-hnRNP F antibodies, as previously described, with minor modifications\textsuperscript{29}. All IHC staining results were assessed by two independent pathologists blinded to the sample origins and the corresponding patient outcomes. ECD and hnRNP F expression was evaluated using a previously described semi-quantitative German scoring system, which assesses protein expression based on staining intensity and area. Scores of 0–5 indicated low ECD and hnRNP F expression (low) in the GC tissue, and scores of 6–7 indicated high ECD and hnRNP F expression (high) in the GC tissue.

Migration and invasion assays
In vitro migration and invasion assays were performed using Transwell chambers, as previously described\textsuperscript{1}.

Western blotting
Western blotting was performed as previously described\textsuperscript{1}.

Experimental in vivo metastasis model
Male NOD-SCID mice (aged 4–5 weeks) were obtained from Charles River Laboratories in China (Beijing). The mice were bred and maintained under defined conditions at the Animal Experiment Center of the College of Medicine (SPF grade), Jinan University. The mice were randomized to allocate into experimental groups by the researchers blinded to the subject outcomes. In vivo metastatic assays were performed as previously described, with minor modifications\textsuperscript{30}. Briefly, five NOD-SCID mice in each experimental group were injected with luciferase-labeled SGC-7901-Luc-NC or SGC-7901-Luc-ECD shRNA-transduced cells (2 × 10\textsuperscript{6} cells in 0.2 ml\textsuperscript{−1} of PBS) via their tail veins. The resultant metastatic foci in the lungs were visualized 2 months after tumor implantation. Animal experiments were approved by the Laboratory Animal Ethics Committee of Jinan University and conformed to the legal mandates and national guidelines for the care and maintenance of laboratory animals.

Co-immunoprecipitation (Co-IP)
Cells were transfected with Flag-ECD, Flag-hnRNP F (Flag-F), HA-ZFP91, or Flag (negative control) vectors for 48 h. Co-IP was subsequently performed using anti-Flag or HA antibodies (MBL), and the immune complexes were captured on protein A/G agarose beads (Santa Cruz, USA) and separated by SDS-PAGE. The SDS-PAGE gels were stained with silver. Protein expression was detected by western blotting using the indicated antibodies.

Protein identification by mass spectrometry
The differential gel bands and their corresponding negative gel bands were excised and digested using in-gel trypsin. The extracted peptide mixtures were analyzed using nano-LC-MS/MS, as previously described\textsuperscript{31}. Proteins were identified using the Mascot (v2.3.02) program against the Uniprot human protein database (released Dec. 2014) using the default settings. Protein scores were ≥40, and unique peptides were ≥2.

In vivo ubiquitination assay
This procedure was performed as previously described\textsuperscript{22}. Briefly, the cells were co-transfected with the indicated plasmids for 36 h, then treated with 10 μM MG132 for 4 h prior to harvesting. The cells were lysed in RIPA buffer with protease inhibitor cocktail (Roche, Switzerland). Flag-hnRNP F was immunoprecipitated using anti-Flag antibodies and protein A/G agarose beads. Polyubiquitinated hnRNP F was detected using anti-HA antibodies.
Statistical analysis

Two-tailed Student’s t-tests or Mann–Whitney U tests were used for comparisons between two groups. Survival analysis was performed using the Kaplan–Meier method and the log-rank test. Statistical analyses were performed using Prism 5.0 software. Data are presented as the mean ± SEM unless otherwise stated. *p < 0.05 or **p < 0.01 was considered statistically significant.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81772998, 81672393), the R&D Plan of Guangzhou (201704020115), the Yangcheng Scholars program from the Ministry of Education of Guangzhou (1201561583), Innovative Research Team of Ministry of Education of Guangzhou (1201610015), the R&D Plan of Guangdong (2017A020215096), and the National Funds of Developing Local Colleges and Universities (B16056001).

Author details

1. Biomedicine Research Center, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China. 2. Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 510150, China

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at https://doi.org/10.1038/s41419-018-0525-x.

Received: 7 February 2018 Accepted: 23 March 2018 Published online: 30 April 2018

References

1. Xu, S.H. et al. ACK1 promotes gastric cancer epithelial-mesenchymal transition and metastasis through AKT-POU2F1-ECD signalling. J. Pathol. 236, 175–185 (2015).

2. Deng, N. et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61, 673–684 (2012).

3. Garen, A., Kauvar, L. & Lepesant, J. A. Roles of ecdysone in Drosophila development. Proc. Natl Acad. Sci. USA 74, 5099–5103 (1977).

4. Kim, J.H. et al. Role of mammalian Ecdysoneless in cell cycle regulation. J. Biol. Chem. 284, 26402–26410 (2009).

5. Kim, J.H., Gurumurthy, C.B., Band, H. & Band, V. Biochemical characterization of human Ecdysoneless reveals a role in transcriptional regulation. Biocell 39, 9–19 (2015).

6. Mir, R.A. et al. A novel interaction of ecdysoneless (ECD) protein with R2TP complex component Rब्लूई.1 is required for the functional role of ECD in cell cycle progression. Mol. Cell. Biol. 36, 886–899 (2015).

7. Zhao, X. et al. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. Breast Cancer Res. Treat. 134, 171–180 (2012).

8. Dey, P. et al. Overexpression of ecdysoneless in pancreatic cancer and its role in oncogenesis by regulating glycolysis. Clin. Cancer Res. 18, 6188–6196 (2012).

9. Xu, S.H. et al. Amplification of ACK1 promotes gastric tumorigenesis via ECD-dependent p53 ubiquitination degradation. Oncotarget 8, 12705–12716 (2017).

10. Geuens, T., Bouhy, D. & Timmerman, V. The hnrNpl family: insights into their role in health and disease. Hum. Genet. 135, 851–867 (2016).

11. Chang, E.T., Pai, P.R., Yang, G., Nguyen, D.M. & carrier, F. Heterogeneous ribonucleoprotein A18 (hnRNPA18) promotes tumor growth by increasing protein translation of selected transcripts in cancer cells. Oncotarget 7, 10578–10593 (2016).

12. Wang, F. et al. SPSB1-mediated HnRNPA1 ubiquitylation regulates alternative splicing and cell migration in EGFR signaling. Cell. Res. 27, 540–558 (2017).

13. Tamayo, J.V., Teramoto, T., Chatterjee, S., Hall, T.M. & Gavis, E.R. The Drosophila hnrNpl F/A homolog gloudn uses two distinct RNA-binding modes to diversify target recognition. Cell Rep. 19, 150–161 (2017).

14. Hong, X. et al. PTEN antagonises Tct1/hnrNRPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut 63, 1635–1647 (2014).

15. Cammas, A. et al. hnrNPA1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression. Oncotarget 7, 16793–16805 (2016).

16. Domínguez, C., Fissette, J.F., Chabot, B. & Allain, F.H. Structural basis of G-tract recognition and engagement by hnrNPA F quasi-RMVs. Nat. Struct. Mol. Biol. 17, 853–861 (2010).

17. Gameau, D., Revil, T., Fissette, J.F. & Chabot, B. Heterogeneous nuclear ribonucleoprotein F/A proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 280, 22641–22650 (2005).

18. Tang, X., Kane, V.D., More, D.M. & More, D.J. hnrNPA F directs formation of an exon 4 minus variant of tumor-associated NADH oxidase (ENO2X). Mol. Cell. Biochem. 357, 55–63 (2011).

19. Balusubramaniam, M., Day, B.W., Schoen, R.E. & Geizenberg, R.H. Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res. 66, 763–769 (2006).

20. Scott, D.C. et al. Two distinct types of E3 ligases work in unison to regulate substrate ubiquitinylation. Cell 166, 1198–1214 e1214 (2016).

21. Kong, S. et al. Endolysosomal reticulum-resident E3 ubiquitin ligase Hrd1 controls B-cell immunity through degradation of the death receptor CD95/Fas. Proc. Natl Acad. Sci. USA 113, 10394–10399 (2016).

22. Hong, J. et al. CHK1 targets spleen tyrosine kinase (Sck) for proteolysis in hepatocellular carcinoma. J. Clin. Invest. 122, 2166–2175 (2012).

23. Zhu, W. et al. KRBP3 promotes proliferation of non-small cell lung cancer cells through regulating Sp1/HDAC2/p27. Theranostics 7, 3078–3089 (2017).

24. Zhi, X. et al. E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation. Cancer Res. 73, 385–394 (2013).

25. Belé, A. et al. The cell cycle regulator ecdysoneless cooperates with H-Ras to promote oncogenic transformation of human mammary epithelial cells. Cell Cycle 14, 990–1000 (2015).

26. Mandler, M.D., Ku, L. & Feng, Y.A. Cytoplasmic quaking I isoform regulates the hnrNPA F/A-dependent alternative splicing pathway in myelinating glia. Nucleic Acids Res. 42, 7319–7329 (2014).

27. Jin, X. et al. An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via Lys63-linked ubiquitination. J. Biol. Chem. 285, 39439–39457 (2010).

28. Wang, J.X., Li, Q. & Li, P.F. Apoptosis repressor with caspase recruitment domain contributes to chemotherapy resistance by abolishing mitochondrial fission mediated by dynamin-related protein-1. Cancer Res. 69, 492–500 (2009).

29. Huang, J.Z. et al. A peptide encoded by a putative IncRNA HOXB-AS3 suppresses colon cancer growth. Mol. Cell. 68, 171–184 e176 (2017).

30. Huang, J.Z. et al. Down-regulation of TRPS1 stimulates epithelial-mesenchymal transition and metastasis through repression of FOXA1. J. Pathol. 239, 186–196 (2016).

31. Yan, G.R. et al. Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study. Proteomics 12, 2391–2399 (2012).